An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zafgen, Inc.
• Treatments: CKD732

Criteria

Inclusion Criteria:

• Obese volunteers weighing ≥ 50 kg

• BMI ≥ 30 and ≤ 50 kg/m2

• Stable body weight during the past 2 months

• Type 2 diabetes mellitus is allowed

Exclusion Criteria:

• Use of weight loss agents in the past month

• Current, clinically significant eating disorder

• Type 1 diabetes mellitus